

American Association of Nurse Practitioners® 2021 Fall Online Conference Contact Pharmacology CE Hours

Presentation ID	Presentation Title	Topical Area	Presentation Description	Speaker Listing	CE Hours	Pharmacology
F21.4.006	2021 Clinical Practice Guidelines for Best Practice in the Management of Type 2 Diabetes Mellitus	Cardiometabolic	The management of patients with type 2 diabetes mellitus is complex and dynamic. Clinical practice guidelines are updated by the American Diabetes Association yearly and require continuous provider learning to keep up with new research, technology, and treatment to improve outcomes and well-being for patient with diabetes. This presentation will review the 2021 guidelines and apply to current practice.	Susan S. VanBeuge, DNP, APRN, FNP-BC, FAANP	1.05	0.80
F21.3.010	A Structured Approach to De-prescribing Psychiatric Medication	Psychiatric-Mental Health	This presentation will help the provider identify individuals who are good candidates for reducing medications and provide the prescriber with a structured approach to the deprescribing process. Practical application and case examples will be provided.	Erica Ramey, DNP, PMHNP	0.80	0.80
F21.2.046	Adult Onset Type 1 Diabetes: How To Navigate Diagnosis and Management in Primary Care	Cardiometabolic	Type 1 Diabetes is thought of as a condition that primarily occurs in childhood and adolescence, but this condition does occur in adults and is often misdiagnosed as Type 2 diabetes. In fact, Type 1 diabetes is equally likely to happen in the first six decades of life with over 42% of all cases occurring between the ages of 40-60 years of age. And current estimates indicate that as much as 40% of adults diagnosed with Type 2 diabetes actually have Type 1 diabetes. It is critical that primary care nurse practitioners (NPs) understand the distinguishing characteristics of Type 1 diabetes in adults so early detection and recognition can occur. It is equally important NPs appreciate the unique challenges associated with the management and treatment of this unique population. This presentation will utilize case studies to demonstrate the practical application of guidelines and best practices in the primary care setting for the management of Type 1 diabetes in adults.	Angela Thompson, DNP, FNP-C, BC, ADMN, CDCES, FAANP	1.30	0.65
F21.3.049	Best Practices in Migraine Management	Pharmacology	Migraines affect approximately 13% of the population. They are associated with significant pain, suffering and disability. This presentation will provide the learner with the latest recommendations and guidelines regarding the management of patients with migraine and chronic migraine.	Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP	1.00	0.65
F21.2.020	Common Psychotropic Medications in Primary Care: What the PCP Needs to Know	Psychiatric-Mental Health	Primary care providers assist with the provision of care for too many psychiatric patients. It is important to understand the neurobiology in the neurochemistry in making treatment decisions regarding psychotropic medications. We will discuss when mental illness is within the scope of a primary care provider's practice, mechanisms of action and decision-making strategies regarding medication choices and when to refer to psychotherapy. The focus will primarily be on antidepressants, anxiolytics and atypical antipsychotics. Additionally, we will discuss appropriate screening tools for a PCP office setting.	Sattaria (Tari) Dilks, DNP, PMHNP-BC, FAANP	1.25	0.80
F21.1.017	COVID-19: How Did We Get Here?	Diversity, Equity and Inclusion	This presentation will look at some historical facts on medicine and racism that have set the stage for the inequities exacerbated in the COVID-19 pandemic.	Nneka O. Sederstrom, PhD, MPH, MA, FCCP, FCCM	Under review	Under review
F21.4.053	Current Advances in Stem Cell Transplant	Acute Care	Stem cell transplantation is a rapidly growing medical field with exciting growth. The purpose of this presentation will be to provide an overview of progress being made in this practice. Various topics will include advances in reduced intensity chemotherapy regimen transplants, chimeric antigen receptor (CAR) T-cell therapy, and new graft versus host disease therapies.	Catherine Lucid, ACNP-BC	0.95	0.00
F21.2.019	Drugs as the Etiology: Case Studies in Drug-Induced Symptom Presentation	Pharmacology	Medication adverse effects are a commonly identified cause of patient complaints, and several are well known and easily identified. New onset lightheadedness: look for the new antihypertensive. New onset constipation: look for the anticholinergic. Unfortunately, sometimes the relationship is not apparent, or we do not know about the culprit medication. This presentation presents case studies from everyday settings in which drugs are the "not so obvious" etiology of symptoms that led to invasive, expensive, and/or unnecessary work-ups.	Sally K. Miller, PhD, APRN, AGACNP-BC, AGPCNP-BC, FNP-BC, PMHNP-BC, FAANP	Under review	Under review
F21.4.054	Evaluating the 12-lead ECG: Concepts for Interpretation of Acute and Chronic Changes with Case Study Analysis	Acute Care	Prerequisite: Proficiency in rhythm assessment is essential. The 12-lead electrocardiogram is one tool available to the advanced practice registered nurse that contributes to the assessment and diagnosis of acute and chronic cardiac disease. This program, designed for clinicians across the spectrum of primary and acute care, begins with the presentation of core concepts in 12-lead ECG interpretation, including analysis of rate, rhythm, intervals, axis and morphologic assessment of all complex waveforms. The program culminates with the critical application of all concepts in select case study presentations.	Sally K. Miller, PhD, APRN, AGACNP-BC, AGPCNP-BC, FNP-BC, PMHNP-BC, FAANP	4.20	0.00
F21.4.052	Evaluation and Management of Venous Thromboembolism	Acute Care	Venous thromboembolism (VTE) includes deep vein thrombosis and pulmonary embolism. The mortality for DVT and PE is 6% and 12% respectively and the economic burden of VTE is greater than 1.5 billion dollars yearly. This presentation will review the etiology, prevalence, pathogenesis and risk factors for VTE. Typical clinical presentations will be summarized. Clinical decision rules and pharmacological strategies will be presented for the treatment of DVT and PE. Case studies will focus on how to apply evidence based guidelines for the management of this important	Joanne Thanavaro, DNP, APRN, AGPCNP-BC, AGACNP-BC, DCC, FAANP	0.90	0.45
F21.2.040	Glutamate in Treatment-resistant Depression: The Who and What of Es/ketamine	Psychiatric-Mental Health	Many limitations exist in analyzing the science around treatment resistant depression. A number of elements, such as accurate diagnosis, are key in effective treatment, but most important are the advances in understanding new neurobiology. Glutamate pathways and the interaction with other neuro-messengers reveals new understandings and potential therapies. This presentation reviews the research and underpinnings of advances in treatment resistant depression, outlines available glutaminergic treatments such as ketamine and esketamine, and potential interventions of the future.	Mary Ann Nihart, MA, APRN, PMHCNS-BC, PMHNP-BC	Under review	Under review

**The hours displayed are estimated as of 10/1/2021. Note: CE contact hours and pharmacology hours are subject to change.
Some sessions do not have pharmacology hours.**

Presentation ID	Presentation Title	Topical Area	Presentation Description	Speaker Listing	CE Hours	Pharmacology
F21.4.026	Inpatient Diabetes Management: An Opportunity to Optimize	Cardiometabolic	Current evidence shows glycemic control is essential in decreasing inpatient mortality and morbidity particularly in the cardiometabolic patient, yet studies are limited in number and size in the most effective way to do this outside of intravenous insulin. Care of the patient with hyperglycemia and/or diabetes in the hospital setting can be daunting. This presentation will focus on safely and aggressively treating blood glucoses to target using insulin therapies. Cases will cover initiating and individualizing insulin therapy in various patient populations. Specific cardiology patient examples will be provided on troubleshooting difficult intravenous insulin titrations, transitioning from intravenous to subcutaneous insulin, and dealing with NPO status, tube feedings, TPN, steroids and patients with chronic kidney or end-stage renal disease.	Melanie E. Mabrey, DNP, ACNP-BC, BC-ADM, FAANP	Under review	Under review
F21.2.030	Keeping It Simple: The Power of Brief Therapeutic Interventions	Psychiatric-Mental Health	Compelling evidence suggests that both medications and therapeutic interventions are effective in the treatment of psychiatric disorders. The current "state of the science" involves multiple modalities to produce better outcomes than those observed with the use of either psychopharmacology or therapy alone. Nurse practitioners in all settings need to understand how various therapeutic interventions can profoundly influence clients' ability to cope and change. Using the unifying framework developed by Hubble, Duncan and Miller, we examine the four common elements that account for much of the improvement seen in clients, regardless of the approach taken. These constructs are applied to a variety of simple, brief approaches that are easily enacted -- and easily adapted -- to any patient encounter.	Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP	1.20	0.00
F21.3.046	Managing Heart Failure in 2021: Implementing Guideline Recommendations into Practice	Cardiometabolic	Heart failure is a significant cause of cardiovascular morbidity and mortality in the United States. Nurse practitioners need to be knowledgeable of current treatment options to prevent cardiovascular sequela associated with heart failure. Using interactive case-based tutorials, participants will review the current American College of Cardiology/American Heart Association guideline on the management of heart failure, emphasizing practical approaches and clinical pearls to translate scientific evidence into everyday practice to improve patient outcomes. Emphasis will be on treatment goals based on recent evidence highlighting the importance guideline-directed medical therapy to reduce morbidity, mortality, and improve quality of life.	Jennifer Ballard-Hernandez, DNP, NP, FACC, FAHA, FAANP	1.15	0.85
F21.3.016	Managing Hypertension in Adults Utilizing an Evidence-Based Approach	Cardiometabolic	Hypertension remains a prevalent disease in the United States that is associated with significant morbidity and mortality. Nurse practitioners need to be knowledgeable of current treatment options to prevent cardiovascular sequela associated with untreated hypertension. Using interactive case-based tutorials, participants will review the current American College of Cardiology/American Heart Association guideline on the management of hypertension, emphasizing practical approaches and clinical pearls to translate scientific evidence into everyday practice to improve patient outcomes. Emphasis will be on treatment goals for adults based on recent evidence, the benefits and risks of lower targets for systolic blood pressure, and the importance of blood pressure monitoring. Use of lifestyle modification and guideline-directed medical therapy will be discussed to reduce cardiovascular events and improve patients' quality of life.	Jennifer Ballard-Hernandez, DNP, NP, FACC, FAHA, FAANP	1.00	0.75
F21.4.050	Managing the Sickle Cell Patient in the ED: They are Not All Drug Seekers	Acute Care	This timely presentation will discuss the management of patients with sickle cell disease and their management in the emergency department. National focus on the opioid crisis has affected nurse practitioner management of pain for patients who do experience pain. The presenter will discuss recent findings and treatment modalities for our patients who suffer with excruciating pain and are often under treated for the real disease of sickle cell.	Elda Ramirez, RN, PhD, FNP-BC, FANP, FAEN, FAAN	0.70	0.35
F21.3.039	Managing Type 2 Diabetes Mellitus: Beyond Metformin	Cardiometabolic	Management of Type 2 Diabetes Mellitus is a complex and ever-changing landscape. Patients with type 2 diabetes mellitus have unique needs in a complex disease state. This presentation will review the practice guidelines and empower the nurse practitioner to improve outcomes with current treatment therapies available. This presentation will include application of case studies to illustrate use of practice guidelines and modifying treatment plans as	Susan S. VanBeuge, DNP, APRN, FNP-BC, FAANP	Under review	Under review
F21.1.039	Medical Marijuana and CBD: The Blunt Basics	Pharmacology	The basic pharmacology of THC and CBD will be discussed. A review of the commonly used dosage forms, the pros/cons to their use and the basic pharmacokinetic differences will be introduced. Further, the presentation will address the endocannabinoid system and how THC and CBD interact with that system. The side effects and drug interaction profiles of THC and CBD will be presented.	Andrew Peterson, PharmD, PhD	0.90	0.90
F21.1.046	Multidisciplinary Case Studies for Cardiometabolic Disease	Cardiometabolic	This panel discussion will include case studies of complex patients with cardiometabolic diseases. A round table discussion including a panel of cardiovascular, obesity and endocrine subject matter experts will review case studies and treatment plans. We will discuss how treatment decisions for one chronic disease can affect decision making for another disease. This moderated panel discussion will be interactive.	Angela Golden, NP, FNP-C, FAANP; Angela Thompson, DNP, FNP-C, BC-ADM, CDE, FAANP; Margaret "Midge" Bowers, DNP, FNP-BC, AACC, CHSE, FAANP; and Colleen Walsh-Irwin, DNP,	0.90	0.50
F21.1.050	Neuroscience & Neuroplasticity: The Keys to Treating Substance Use Disorders	Psychiatric-Mental Health	Patients struggle with addictions and substance use disorders (SUDs) and utilize all disciplines of the health care spectrum. This presentation will focus on the most commonly abused substances including opioids. APRNs attending this presentation will gain an understanding of the complexities and neuroplasticity of the brain related to SUDs which "set the stage" for pharmaceutical intervention. A review of medications for various substance use disorders as well as techniques to pharmaceutically manage withdrawal and overdose will be presented.	Laura Leahy, DrNP, APRN, PMH-CNS/FNP, CARN-AP, FAANP, FAAN	1.30	0.85
F21.3.048	NP Entrepreneurs as Risk Takers	Business/Professional	The future of health care will depend upon nurse practitioners (NPs) taking the leap and becoming entrepreneurs. Many NPs are disenfranchised with the medical model of health care delivery focusing on numbers of patients seen as a measure of productivity. Couple this with the lack of primary care physicians, the reality of NPs creating a seismic shift in health care is inevitable. Nurse practitioner entrepreneurs (NPE) will need to understand the risks associated with business ownership and be willing to take them knowing they can be successful.	Lynn Rapsilber, DNP, APRN, ANP-BC, FAANP	0.80	0.00
F21.4.030	Order from Chaos: Trauma-informed Leadership	Psychiatric-Mental Health	This presentation will examine the role of the nurse practitioner leader in disaster situations, from preparation to the event itself, and through the aftermath. Concepts related to leadership style, management of healthcare resources and personnel, communication, and care for survivors and caregivers will be discussed. The Las Vegas mass casualty event of October 1, 2017 will serve as the case study for these concepts.	Rhone D'Errico, DNP, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE	Under review	Under review

**The hours displayed are estimated as of 10/1/2021. Note: CE contact hours and pharmacology hours are subject to change.
Some sessions do not have pharmacology hours.**

Presentation ID	Presentation Title	Topical Area	Presentation Description	Speaker Listing	CE Hours	Pharmacology
F21.1.030	Pharmacogenomics: Precision Medicine & Depression Treatment	Psychiatric-Mental Health	Pharmacogenomics is the study of how genes affect a person's response to drugs. This science has given rise to the practice of "precision medicine," which combines pharmacology (the study of medication) and genomics (the study of genes and their functions) to help prescribers make more personalized medication choices. These include which medications to prescribe to different individuals and what doses will have the best effects. This presentation integrates concepts of neurobiology and neuropathology with genetics and genomics to produce new models for diagnosis and personalized treatment for major depressive disorder. The results of the GUIDED study are presented to highlight the efficacy of this approach.	Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP	0.85	0.65
F21.1.009	Pharmacologic Considerations in Acute Respiratory Distress Syndrome	Pharmacology	This presentation will discuss the evidence-based treatment of patients with Acute Respiratory Distress Syndrome (ARDS) with a focus on pharmacologic interventions. This presentation will describe the specific pharmacologic interventions and their evidence-based role and scope in the treatment of ARDS.	Anthony Angelow, PhD, ACNPC, FAEN, FAANP	1.00	1.00
F21.3.009	Pharmacologic Management of Sleep Disorders: Targeting the Physiology	Pharmacology	Sleep disorders are a common symptom in the primary care setting, and pharmacotherapeutic options abound! Benzodiazepine receptor agonists, melatonin-based options, antidepressants, antipsychotics, nutraceuticals are just a few available options. Considering the physiology of sleep and sleep disorders provides a foundation for the best medication selection. This presentation reviews the physiology of sleep disorders and evaluates best drug options based on treatment target.	Sally K. Miller, PhD, APRN, AGACNP-BC, AGPCNP-BC, FNP-BC, PMHNP-BC, FAANP	1.05	1.05
F21.1.016	Pharmacology for Obesity Treatment: Today and Tomorrow	Pharmacology	Seventy percent (70%) of Americans have pre-obesity or have the serious, chronic and relapsing disease of obesity. This presentation will review the current medication options including off label, obesogenic medication alternatives for treating obesity. A case study approach will be utilized to demonstrate medication selection. Additionally, a look at what is ahead for the treatment of obesity will conclude the presentation.	Angela Golden, DNP, FNP-C, FAANP,	0.90	0.90
F21.2.009	Practical Pharmacogenetics	Pharmacology	This program is designed to increase the knowledge and skills necessary for the nurse practitioner to use pharmacogenomic (PGx) principles in everyday practice. The learner will be exposed to the rationale and process for applying PGx in clinical practice, interpreting basic pharmacogenomics results and then applying them in a clinical setting.	Andrew Peterson, PharmD, PhD	0.90	0.70
F21.3.036	Prevention of Cardiometabolic Disease	Cardiometabolic	This presentation will focus on current evidence that defines risk for cardiometabolic disease. We will discuss cardiovascular disease, diabetes, and hyperlipidemia as they intersect in the pathophysiology and disease progression of cardiometabolic disease. We will discuss and apply case studies that illuminate both the prevention and treatment of atherosclerotic cardiovascular disease. This conversational session will include case study discussion and application for both the primary care provider and the specialist who aim to promote healthy aging.	Allison Dimsdale, DNP, NP-C, AACC, FAANP	Under review	Under review
F21.3.029	Primary Care Approach to Hypothyroidism	Cardiometabolic	Hypothyroid disease is commonly managed in primary care. This presentation will take a methodical approach to the diagnosis, treatment, and ongoing management of the types of hypothyroid disease seen by primary care providers. We will detail the pharmacology and application of best practices when prescribing, titrating, and managing your patients' hypothyroid needs.	Susan S. VanBeuge, DNP, APRN, FNP-BC, FAANP	1.00	0.65
F21.2.037	Racism as a Structural Determinant of Health	Diversity, Equity and Inclusion	Addressing racism as a root causes of disparities, inequities and injustices is essential for achieving health equity. This presentation focuses on racism as both a structural and a social determinant of health. It contextualizes systemic racism, both historically and presently, and provides strategies for building structural competency and dismantling systemic racism.	Sandra Davis, PhD, DPM, ACNP-BC, FAANP; Danielle McCamey, DNP, ACNP-BC, FCCP	0.85	0.00
F21.1.047	Racism, COVID-19 and the Crisis of Standards of Care	Diversity, Equity and Inclusion	In this presentation we will discuss how the original crisis standards of care and scoring protocols promoted inequities and exacerbated systemic racism at the beginning of the COVID-19 pandemic.	Nneka O. Sederstrom, PhD, MPH, MA, FCCP, FCCM	1.05	0.00
F21.3.030	Rx Update: A 2021 Look at New Agents and Indications for Mood and Psychotic Disorders	Pharmacology	Antipsychotic medication is a class always in revision. While all antipsychotics control psychoses, it is a never-ending challenge to minimize adverse effects; simultaneously new indications are consistently being developed. This presentation is designed for non-psychiatric providers who want to advance their skill set with respect to selection and application of antipsychotic and mood stabilizing medications in the primary care setting.	Sally K. Miller, PhD, APRN, AGACNP-BC, AGPCNP-BC, FNP-BC, PMHNP-BC, FAANP	1.05	1.05
F21.3.007	Seeing the Big Picture: Integrating Social Determinants of Health into Your Clinical Practice	Diversity, Equity and Inclusion	Whether it is Covid-19 infection rates, maternal mortality, or cancer survival rates, racial inequities are pervasive in our health system. In this discussion we will take a deep dive exploring how institutionalized racism is a social determinant of health and we will review the most up to date research for integrating social determinant of health screening into clinical practice. By better understanding patients' social determinants of health, we can help create a more equitable system and improve health outcomes for our patients.	Courtney Pladsen, DNP, FNP-BC, RN	0.90	0.00
F21.1.020	Ten Essentials Every Practitioner Must Know: The Importance of Integrated Care	Psychiatric-Mental Health	The challenges of 2020 produced increasing numbers of individuals impacted by anxiety and depression. Symptoms of trauma and psychosis have been exacerbated and suicide has increased. Most people seek treatment first from their primary care practitioner, but the many complexities of psychiatric disorders necessitate working across specialties. For this reason, essential understandings of neurobiological and psychological underpinnings of depression, symptom recognition, differential diagnosis, challenges in managing symptoms, new options for treatment, and interprofessional collaboration present compelling elements all health care providers must keep in mind. These elements are condensed into the "Ten Essentials" outlined in this presentation.	Mary Ann Nihart, MA, APRN, PMHCNS-BC, PMHNP-BC	Under review	Under review
F21.4.028	The Best Businesses to Start for Less Than 2K	Business/Professional	Have you ever wanted to start a business but stopped thinking about doing so because of the price? Well, good news! This presentation will outline three business ideas for an NP to start for less than 2K.	Scharmaine Lawson-Baker, FNP, PMHNP, FAANP, FAAN	Under review	Under review

**The hours displayed are estimated as of 10/1/2021. Note: CE contact hours and pharmacology hours are subject to change.
Some sessions do not have pharmacology hours.**

Presentation ID	Presentation Title	Topical Area	Presentation Description	Speaker Listing	CE Hours	Pharmacology
F21.1.037	The Bridge Over Troubled Waters: Exploring Disparities and Building Trust Amongst BIPOC Populations at End of Life	Diversity, Equity and Inclusion	With our ever-expanding landscape of medical advancements, our elderly or chronically ill populations have many routes to extend life longer than in previous generations. We insert and bypass, dialyze and reconstruct. But what happens when we cannot fix, heal or reverse? Palliative care aims to relieve pain and suffering and increase quality of life while ushering the most vulnerable patients to a path of comfort that encompasses their physical, mental and spiritual well-being. While palliative care and hospice care are readily available, populations of color are less apt to receive this high-quality specialized care at or towards end of life. With likely many factors at play, we will explore how trust, or lack thereof, as well as misconceptions and failed communication ultimately lead to this disparity.	Rachel Butler, ARNP, FNP-BC	Under review	Under review
F21.1.026	The Gut Microbiome and Cardiometabolic Risks	Cardiometabolic	Over the last decade advances have been made in understanding the gut microbiome and the relationship to disease. The presentation will discuss the significance of the gut microbiome and how an imbalance contributes to disease. Growing evidence is linking the gut microbiome to cardiometabolic risks. The presentation will look into the association of the microbiome, cardiometabolic risks and the latest evidence-based treatments.	Christy Blanco, DNP, APRN, WHNP-BC, FAANP	1.00	0.00
F21.1.007	The Impact of Racial Trauma on Mental Health	Diversity, Equity and Inclusion	This presentation will include the history of Blacks in America. The systemic racism that has remained in place since the end of slavery has resulted in ongoing racial trauma and injustices to Black people, such as racial profiling, voter suppression and overrepresentation in the criminal justice system. Enduring constant prejudice, discrimination and bias takes a toll on one's mental health. The complexities associated with the re-traumatization of Black people, and the broadened awareness of social and racial injustices, have increased. As the struggle for equality continues, it is critically important for Black people, employers, and organizations to carefully consider the effect of these repeated images and videos on the mental health of black people.	Irene W. Bean, DNP, FNP-BC, PMHNP-BC, FAANP	0.85	0.00
F21.2.017	The Link Between Your Identity and How You "Show Up" as a Leader	Diversity, Equity and Inclusion	Our identities not only shape how we interact within our chosen circles, but also how we show up as leaders in our professional and clinical environments. As administrators, clinicians and practitioners, the social groups that we belong to have an impact on our behaviors, cognitive decision-making processes, and our consideration of different perspectives. Conversely, our identity groups also impact how we are perceived and treated by others. We will explore social identity and leadership, the conscious and subconscious ways that we interact within our interdisciplinary teams, and our potential leadership opportunities towards our patients and the communities that we serve. In this interactive workshop, we will gain self-awareness by mapping social identities and exploring how our identities are connected to our effectiveness as a leader; understand how our visible and invisible identities support our leadership – and how they may create bias or blind spots; uncover opportunities to foster a culture of diversity, equity and inclusion in our scope of influence as a leader-practitioner; and challenge our thinking through small-group sense-making discussions – and identify thought partners and accountability partners as we commit to individual	Emma Flack, EdD, MBA	0.90	0.00
F21.1.040	The Neurobiology of Trauma: Basis of Symptom Development	Psychiatric-Mental Health	Trauma, especially extended or repetitive trauma, sets the stage for neurobiological changes that inform the observable symptoms, especially those associated with Post Traumatic Stress Disorder (PTSD). This knowledge assists with determination of medication or therapeutic approaches to facilitate recovery and resiliency. We are currently in unprecedented times due to trauma associated with pandemic and unknown sequela of both the pandemic and COVID 19. We will explore what PCPs might expect to see in the future based on our past knowledge of widespread traumatic events and the early data on a worldwide pandemic which has affected every area of life as we have known it. We will discuss screening tools, treatment strategies, and when there is a need to refer.	Sattaria (Tari) Dilks, DNP, PMHNP-BC, FAANP	1.10	0.30
F21.2.047	The NP's Role in Optimizing Maternal Care for BIPOC	Diversity, Equity and Inclusion	By 2045, people of color will be the majority of the United States population; however, racial and ethnic disparities in women's health continue to persist. This presentation will address the racial and ethnic disparities in maternal care and the role of nurse practitioners in optimizing and improving maternal care for BIPOC communities.	Jamille Nagtalon-Ramos, EdD, MSN, WHNP-BC, IBCLC, FAANP	1.00	0.00
F21.3.047	The Professional World of Black, Indigenous, Latinx and Other Nurses of Color (BILNOC): Facing Racism	Diversity, Equity and Inclusion	The year 2020 shined a light on how pervasive and that systemic racism is alive and well in American institutions. Of course, health care is no different. The world has heard and learned much on how the social determinants, especially COVID, has been killing Black, Brown and Indigenous patients. While the health care profession is learning more and better ways to care for patients of color breaking down racist barriers facing patients, nursing, rated the most trusted profession the past two decades, is not exempt from systemic racism. Learn about the barriers facing Black, Brown and Indigenous students to being a nurse, how nurses and nurse practitioners of Color face racism in practice, education and research.	Sheri Rickman-Patrick, DNP, APRN, FNP-BC	1.10	0.00
F21.4.051	The Riddle of Children in the Emergency Room Solved: Or, So You Think	Acute Care	The pediatric population is a unique subset seen in health care that many refer to as "not just small adults." The complexities of the growing body, immune system and development are unique. Their immune systems react differently and if unimmunized, the job becomes more complicated. They present with illnesses and respond to treatments differently than their adult counterparts.	Tresa Zielinski, DNP, RN, APRN, CPNP-PC	0.80	0.40
F21.3.050	Understanding Suicidality: Assessment, Treatment and Prevention for the Health Care Provider	Psychiatric-Mental Health	Repeated in F21.4.009. This presentation describes strategies that health care providers can utilize to understand, assess for, treat and prevent suicidality in diverse health care settings. The prevalence, epidemiology and psychology of suicidality will be reviewed, including a discussion of suicide among selected high-risk populations, including individuals who identify as LGBTQ, veterans, minorities and health care professionals. This presentation includes approaches to training primary care office staff in suicide awareness and prevention. Safety planning, documentation and follow up are discussed, and self-care for the health care provider will be reviewed. The goal of this activity is to empower health care providers to confidently understand and address suicide risk in their specific patient	Rhone D'Errico, DNP, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE	1.00	0.00
F21.1.029	Updates and Case Studies: Sepsis Case Management	Pharmacology	This presentation will provide an overview of the evidence-based management of sepsis with a focus on pharmacologic interventions. This presentation will describe the specific pharmacologic interventions and their evidence-based role and scope in the treatment of patients with sepsis.	Anthony Angelow, PhD, ACNPC, FAEN, FAANP	0.95	0.95

**The hours displayed are estimated as of 10/1/2021. Note: CE contact hours and pharmacology hours are subject to change.
Some sessions do not have pharmacology hours.**

Presentation ID	Presentation Title	Topical Area	Presentation Description	Speaker Listing	CE Hours	Pharmacology
F21.1.019	Updates in the Pharmacologic Management of Asthma	Pharmacology	This presentation will focus on the pharmacologic management of asthma with emphasis on understanding pathophysiology and testing to guide medication management. Clinical exemplars will be used to enhance the understanding of the appropriate medication management options.	Tracy Estes, PhD, DNP, RN, FNP-BC	0.95	0.75
F21.1.049	Updates in the Pharmacologic Management of COPD	Pharmacology	This presentation will focus on the pharmacologic management of chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. There will be special emphasis placed on understanding pathophysiology and testing to guide medication management. Clinical exemplars will be used to enhance the understanding of the appropriate medication management options.	Tracy Estes, PhD, DNP, RN, FNP-BC	1.00	1.00
F21.4.016	What is Cardiorenal Syndrome and When Should I Worry?	Cardiometabolic	This presentation will clearly describe what is known about the types of cardiorenal syndrome and review heart-kidney pathophysiology. Diagnosis and management will be discussed in the context of both primary and acute care populations. Clinical application will be demonstrated with the use of case studies.	Carolina D. Tennyson, DNP, ACNP-BC, AACC	Under review	Under review
F21.2.010	When ADHD is Really TRAUMA: Differential Diagnosis and Special Treatment Considerations for Children & Adolescents	Psychiatric-Mental Health	This presentation will assist the mental health professional with differentiating between ADHD, trauma symptoms and related disorders. Discussion will include treatment strategies that may exacerbate and/or alleviate related symptoms based on the underlying condition.	Erica Ramey, DNP, PMHNP	0.70	0.20
F21.1.006	Women are Different: Understanding the Complex Female Heart	Cardiometabolic	Heart disease is the number one killer of women, yet under recognized and under treated. Women present late into the active disease process for a variety of social disparities. Plus, providers often lack the understanding of the difference of the female heart and pathology. This presentation is a fast-paced program that intertwines the social disparities of women presenting in cardiology with the unique risk factors and presentation of women. The pathophysiology starts on the electron rings of oxygen, then the cellular function, inflammatory responses, and endothelial cell dysfunction to the microvascular coronary artery disease that creates atypical pain patterns to large vessel coronary artery disease with the resulting mortality and morbidity burdens of women. All NPs providing care and guidance to women need to understand the unique risks, cardiac pathology, and importance of preventative cardiology to make a difference in decreasing the number one killer of women.	Maria C. Kidner, DNP, FNP-BC, FAANP	1.05	0.00